comprehensive -WSS

comprehensive

author：comprehensive 2025-09-27 19:50:06 - browse：8

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Ultragenyx gene therapy for rare liver ailment succeeds in late

entertainment

WSS

The simple reason for the increase in autism diagnosis

How to increase colonoscopy rates? Looks like an AI can help

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Illumina to lay off 10% of research and development team

How to increase colonoscopy rates? Looks like an AI can help

Change Healthcare can notify patients about the breach, HHS says

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Wikipedia

Trump demands the U.S. pay no more for drugs than other countries … again

Intellia reports positive results for its CRISPR

Bright Health sells Medicare Advantage business to Molina

The strange history of BMI, the body mass index

Novavax promises a turnaround & Lilly roils the obesity market

Brazil's Jair Bolsonaro is barred from running for office until 2030

Wildfire smoke exposes gaps in outdoor worker protections

Woman returns to dialysis after doctors remove transplanted pig kidney

As demand for Covid shots wanes, Moderna seeks its next success

Tuskegee Airman Raymond Cassagnol dies at 102

focus

Synthetic human embryos? Researchers say term is overblown

ADA: All diabetes patients should be screened for liver condition

BMI, flaws aside, is found to be useful estimate of body fat in youth

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Newly formed Hurricane Beatriz sweeps close to Mexico's southwest Pacific coast

FDA's Pazdur wants cancer trials to range beyond China alone

hotspot

entertainment

focus

Wikipedia